BAX 8-K
Baxter International Inc (BAX)
8-K
2025-10-21
For: 2025-10-16
View Original
Added on
April 11, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 16, 2025
| (Exact name of registrant as specified in its charter) | |||||
| (State or other jurisdiction of incorporation) | |||||
| (Commission File Number) | (I.R.S. Employer Identification No.) | ||||
| (Address of principal executive offices) | (Zip Code) | ||||
( | |||||
| (Registrant’s telephone number, including area code) | |||||
| (Former name or former address, if changed since last report) | |||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 16, 2025, Heather Knight notified Baxter International Inc. (the “Company”) of her decision to resign as the Company’s Executive Vice President, Chief Operating Officer (“COO”) and interim group president of Medical Products and Therapies (“MPT”), effective as of October 29, 2025 (the “Transition Date”), to join a company in the healthcare industry.
In connection with Ms. Knight’s departure, Andrew Hider, the Company’s President and Chief Executive Officer, will also assume the role of interim group president of MPT effective as of the Transition Date. Additionally, as of the Transition Date, the Company will no longer have a COO.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: October 21, 2025 | BAXTER INTERNATIONAL INC. | |||||||
| By: | /s/ Ellen K. Bradford | |||||||
| Name: | Ellen K. Bradford | |||||||
| Title: | Senior Vice President and Corporate Secretary | |||||||